{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:57:38Z","timestamp":1793876258269,"version":"4.7.0"},"reference-count":156,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.berh.2022.101780","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T08:40:41Z","timestamp":1663922441000},"page":"101780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Osteoporosis and Fragility Fractures: currently available pharmacological options and future directions"],"prefix":"10.1016","volume":"36","author":[{"given":"Hans P.","family":"Dimai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Fahrleitner-Pammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2022.101780_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis","volume":"94","author":"[Anonymous]","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2022.101780_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bone.2016.12.016","article-title":"Use of dual-energy X-ray absorptiometry (DXA) for diagnosis and fracture risk assessment; WHO-criteria, T- and Z-score, and reference databases","volume":"104","author":"Dimai","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101780_bib3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.berh.2022.101780_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s11136-017-1748-5","article-title":"Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS","volume":"27","author":"Svedbom","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.berh.2022.101780_bib5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","article-title":"Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis","volume":"15","author":"Klotzbuecher","year":"2000","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib7","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1210\/jc.2017-02656","article-title":"Persistence of excess mortality following individual nonhip fractures: a relative survival analysis","volume":"103","author":"Tran","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"10.1016\/j.berh.2022.101780_bib8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00198-004-1702-6","article-title":"Epidemiology of osteoporotic fractures","volume":"16","author":"Johnell","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib11","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/bph.15024","article-title":"Overview of treatment approaches to osteoporosis","volume":"178","author":"Langdahl","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"845","key":"10.1016\/j.berh.2022.101780_bib12","article-title":"Diphosphonates in the treatment of myositis ossificans","volume":"2","author":"Bassett","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101780_bib13","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.berh.2022.101780_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040717","article-title":"The effects of various food products on bisphosphonate's availability","volume":"14","author":"Zielinska","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.berh.2022.101780_bib15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1517\/14740338.6.6.663","article-title":"Renal safety of intravenous bisphosphonates in the treatment of osteoporosis","volume":"6","author":"Lewiecki","year":"2007","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.berh.2022.101780_bib16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101780_bib18","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2022.101780_bib19","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging"},{"key":"10.1016\/j.berh.2022.101780_bib20","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/joim.12678","article-title":"Hip fracture risk and safety with alendronate treatment in the oldest-old","volume":"282","author":"Axelsson","year":"2017","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.berh.2022.101780_bib21","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","article-title":"Diphosphonates inhibit hydroxyapatite dissolution in\u00a0vitro and bone resorption in tissue culture and in\u00a0vivo","volume":"165","author":"Fleisch","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.berh.2022.101780_bib22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115407","article-title":"History of risedronate","volume":"137","author":"McClung","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101780_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2022.101780_bib25","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2022.101780_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00198-012-2175-7","article-title":"Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib29","article-title":"Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","volume":"5","author":"Wells","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2022.101780_bib30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1185\/030079908X253717","article-title":"Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies","volume":"24","author":"Harris","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.berh.2022.101780_bib33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101780_bib34","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00198-011-1773-0","article-title":"Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study","volume":"23","author":"Miller","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib35","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2022.101780_bib36","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00198-011-1793-9","article-title":"Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension","volume":"23","author":"Bianchi","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00198-013-2518-z","article-title":"Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies","volume":"25","author":"Miller","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib38","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib39","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234123","article-title":"Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: network meta-analysis followed by factor and cluster analysis","volume":"15","author":"Wen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2022.101780_bib42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2006.01.002","article-title":"Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis","volume":"28","author":"Penning-van Beest","year":"2006","journal-title":"Clin Therapeut"},{"issue":"7","key":"10.1016\/j.berh.2022.101780_bib43","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.berh.2022.101780_bib44","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00198-009-0871-8","article-title":"Comparative gastrointestinal safety of weekly oral bisphosphonates","volume":"20","author":"Cadarette","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib45","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s00198-014-2789-z","article-title":"Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis-reply to Pazianas and Abrahamsen","volume":"25","author":"Tadrous","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2010.1098","article-title":"Exposure to oral bisphosphonates and risk of esophageal cancer","volume":"304","author":"Cardwell","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2022.101780_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4444","article-title":"Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort","volume":"341","author":"Green","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.berh.2022.101780_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140180","article-title":"Oral bisphosphonate exposure and the risk of upper gastrointestinal cancers","volume":"10","author":"Vogtmann","year":"2015","journal-title":"PLoS One"},{"issue":"113","key":"10.1016\/j.berh.2022.101780_bib49","first-page":"2474","article-title":"Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies","volume":"10","author":"Mak","year":"2009","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.berh.2022.101780_bib50","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/jbmr.2058","article-title":"Renal safety in patients treated with bisphosphonates for osteoporosis: a review","volume":"28","author":"Miller","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib51","first-page":"36","article-title":"Bisphosphonate-related osteonecrosis of the jaws","volume":"27","author":"Yeo","year":"2005","journal-title":"Singapore Dent J"},{"key":"10.1016\/j.berh.2022.101780_bib52","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.berh.2022.101780_bib54","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.berh.2022.101780_bib55","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc062268","article-title":"Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis","volume":"355","author":"Armamento-Villareal","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib56","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution","volume":"89","author":"Goh","year":"2007","journal-title":"J\u00a0Bone Joint Surg Br"},{"key":"10.1016\/j.berh.2022.101780_bib57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/17453674.2016.1277412","article-title":"Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab","volume":"88","author":"Austin","year":"2017","journal-title":"Acta Orthop"},{"key":"10.1016\/j.berh.2022.101780_bib58","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116297","article-title":"Bisphosphonates and the risk of atypical femur fractures","volume":"156","author":"Black","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101780_bib61","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/jbmr.2565","article-title":"Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an Ecological analysis","volume":"30","author":"Jha","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib62","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.berh.2022.101780_bib63","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.berh.2022.101780_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116297","article-title":"Bisphosphonates and the risk of atypical femur fractures","volume":"156","author":"Black","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101780_bib65","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate drug holiday and fracture risk: a population-based cohort study","volume":"33","author":"Adams","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib66","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/MLR.0000000000001294","article-title":"Duration of bisphosphonate drug holidays and associated fracture risk","volume":"58","author":"Curtis","year":"2020","journal-title":"Med Care"},{"key":"10.1016\/j.berh.2022.101780_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10629","article-title":"Bisphosphonate drug holidays: evidence from clinical trials and real-world studies","volume":"6","author":"Wang","year":"2022","journal-title":"JBMR Plus"},{"key":"10.1016\/j.berh.2022.101780_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10549","article-title":"Bone quality and fractures in women with osteoporosis treated with bisphosphonates for 1 to 14 years","volume":"5","author":"Malluche","year":"2021","journal-title":"JBMR Plus"},{"key":"10.1016\/j.berh.2022.101780_bib69","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1359\/jbmr.2002.17.2.341","article-title":"Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women","volume":"17","author":"Ott","year":"2002","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib70","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2022.101780_bib71","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2022.101780_bib72","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","article-title":"Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial","volume":"33","author":"Delmas","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101780_bib73","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","article-title":"Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass","volume":"40","author":"Recker","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101780_bib74","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","article-title":"Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101780_bib75","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-010-1302-6","article-title":"Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial","volume":"22","author":"de Villiers","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib76","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jval.2014.01.008","article-title":"Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis","volume":"17","author":"Ellis","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.berh.2022.101780_bib77","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1185\/03007995.2014.908279","article-title":"Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women","volume":"30","author":"Ellis","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.berh.2022.101780_bib78","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008659","article-title":"Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: a systematic review and meta-analysis","volume":"96","author":"Peng","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.berh.2022.101780_bib79","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/phar.1749","article-title":"Bazedoxifene and conjugated equine estrogen: a combination product for the management of vasomotor symptoms and osteoporosis prevention associated with menopause","volume":"36","author":"Umland","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.berh.2022.101780_bib80","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1080\/13697137.2016.1216958","article-title":"CE\/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis","volume":"19","author":"Hadji","year":"2016","journal-title":"Climacteric"},{"key":"10.1016\/j.berh.2022.101780_bib81","first-page":"11","article-title":"Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update","volume":"1","author":"Messalli","year":"2010","journal-title":"Int J Wom Health"},{"key":"10.1016\/j.berh.2022.101780_bib82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103679","article-title":"Molecular basis of bone aging","volume":"21","author":"Corrado","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2022.101780_bib84","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/bs.vh.2020.12.016","article-title":"Hormones and bone loss across the menopause transition","volume":"115","author":"Karlamangla","year":"2021","journal-title":"Vitam Horm"},{"key":"10.1016\/j.berh.2022.101780_bib85","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jbmr.534","article-title":"Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health across the Nation (SWAN)","volume":"27","author":"Greendale","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib86","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212551","article-title":"Menopause hormone therapy: latest developments and clinical practice","volume":"8","author":"Fait","year":"2019","journal-title":"Drugs Context"},{"issue":"7","key":"10.1016\/j.berh.2022.101780_bib87","article-title":"Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials","volume":"2","author":"Torgerson","year":"2001","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.berh.2022.101780_bib88","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2022.101780_bib89","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2022.101780_bib90","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2022.101780_bib91","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/jama.291.18.2212","article-title":"Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women","volume":"291","author":"Banks","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2022.101780_bib92","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.bone.2003.12.021","article-title":"Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study","volume":"34","author":"Bagger","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101780_bib93","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/GME.0000000000000519","article-title":"Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Zhu","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.berh.2022.101780_bib94","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women","volume":"3","author":"Boardman","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2022.101780_bib95","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/13697137.2018.1446931","article-title":"Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis","volume":"21","author":"Scarabin","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.berh.2022.101780_bib96","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/GME.0000000000000227","article-title":"Risk of stroke in healthy postmenopausal women during and after hormone therapy: a meta-analysis","volume":"21","author":"Gu","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.berh.2022.101780_bib97","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101780_bib98","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11914-019-00549-3","article-title":"Update on menopausal hormone therapy for fracture prevention","volume":"17","author":"Stepan","year":"2019","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.berh.2022.101780_bib99","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.berh.2022.101780_bib100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jocd.2008.02.002","article-title":"Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases","volume":"11","author":"Delmas","year":"2008","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.berh.2022.101780_bib101","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A\u00a0single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib102","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.berh.2022.101780_bib103","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib104","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.berh.2022.101780_bib106","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","article-title":"Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease","volume":"106","author":"Broadwell","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.berh.2022.101780_bib107","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 Months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib108","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib109","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib110","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.berh.2022.101780_bib111","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"Solling","year":"2021","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib112","first-page":"11","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.berh.2022.101780_bib113","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 Years later: a narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.berh.2022.101780_bib114","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","article-title":"Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?","volume":"31","author":"Tsvetov","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00774-020-01180-4","article-title":"Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study","volume":"39","author":"Tanaka","year":"2021","journal-title":"J\u00a0Bone Miner Metabol"},{"key":"10.1016\/j.berh.2022.101780_bib116","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000499824","article-title":"Severe, symptomatic hypocalcemia due to denosumab administration: treatment and clinical course","volume":"9","author":"Strickling","year":"2019","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.berh.2022.101780_bib117","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib118","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib119","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1185\/030079908X261087","article-title":"Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting","volume":"24","author":"Rajzbaum","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.berh.2022.101780_bib120","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s00198-010-1498-5","article-title":"Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)","volume":"22","author":"Fahrleitner-Pammer","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib121","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00198-009-1168-7","article-title":"Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis","volume":"21","author":"Stepan","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib122","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bone.2013.11.011","article-title":"Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment","volume":"59","author":"Ma","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101780_bib123","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1359\/jbmr.090527","article-title":"Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate","volume":"24","author":"Dobnig","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib124","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bone.2016.05.004","article-title":"Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment","volume":"89","author":"Fahrleitner-Pammer","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101780_bib125","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101780_bib126","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00198-020-05463-4","article-title":"Efficacy of teriparatide compared with risedronate on FRAX((R))-defined major osteoporotic fractures: results of the VERO clinical trial","volume":"31","author":"Body","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib127","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19877994","article-title":"Update on the safety and efficacy of teriparatide in the treatment of osteoporosis","volume":"11","author":"Minisola","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.berh.2022.101780_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116394","article-title":"Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes","volume":"160","author":"Kellier-Steele","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101780_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174409","article-title":"Abaloparatide: a review of preclinical and clinical studies","volume":"909","author":"Brent","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.berh.2022.101780_bib130","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.berh.2022.101780_bib131","article-title":"Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability","volume":"14","author":"McCloskey","year":"2019","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.berh.2022.101780_bib132","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","article-title":"Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis","volume":"30","author":"Reginster","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101780_bib133","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.maturitas.2016.12.003","article-title":"Abaloparatide: recombinant human PTHrP (1-34) anabolic therapy for osteoporosis","volume":"97","author":"Chew","year":"2017","journal-title":"Maturitas"},{"key":"10.1016\/j.berh.2022.101780_bib134","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","article-title":"Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial","volume":"35","author":"Bilezikian","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.berh.2022.101780_bib135","doi-asserted-by":"crossref","first-page":"10890","DOI":"10.1074\/jbc.M807994200","article-title":"Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation","volume":"284","author":"Veverka","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.berh.2022.101780_bib136","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1359\/jbmr.061002","article-title":"Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation","volume":"22","author":"van Bezooijen","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib137","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"Faseb J"},{"key":"10.1016\/j.berh.2022.101780_bib138","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/jbmr.345","article-title":"Sclerostin is a locally acting regulator of late-osteoblast\/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism","volume":"26","author":"Atkins","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib139","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.berh.2022.101780_bib140","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib141","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib142","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101780_bib143","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with osteopenia","volume":"370","author":"McClung","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib144","first-page":"396","article-title":"Romosozumab treatment in postmenopausal osteoporosis","volume":"376","author":"Cosman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib145","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101780_bib146","first-page":"195","article-title":"Romosozumab versus alendronate and fracture risk in women with osteoporosis","volume":"378","author":"Saag","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101780_bib147","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10211","article-title":"The effect of 1 Year of romosozumab on the incidence of clinical vertebral fractures in postmenopausal women with osteoporosis: results from the FRAME study","volume":"3","author":"Geusens","year":"2019","journal-title":"JBMR Plus"},{"issue":"8","key":"10.1016\/j.berh.2022.101780_bib148","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/jbmr.4563","article-title":"Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease","volume":"37","author":"Miller","year":"2022","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101780_bib149","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3904\/kjim.2013.28.4.387","article-title":"Clinical applications of mesenchymal stem cells","volume":"28","author":"Kim","year":"2013","journal-title":"Korean J Intern Med (Korean Ed)"},{"key":"10.1016\/j.berh.2022.101780_bib150","doi-asserted-by":"crossref","first-page":"17986","DOI":"10.3390\/ijms140917986","article-title":"Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy","volume":"14","author":"Jin","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2022.101780_bib151","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12956","article-title":"Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis","volume":"54","author":"Jiang","year":"2021","journal-title":"Cell Prolif"},{"issue":"143","key":"10.1016\/j.berh.2022.101780_bib152","article-title":"Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial","volume":"10","author":"Lu","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.berh.2022.101780_bib153","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.3892\/mmr.2016.5745","article-title":"Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head: a three-year follow-up study","volume":"14","author":"Chen","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.berh.2022.101780_bib154","unstructured":"ClinicalTrials.gov Safety of cultured allogeneic adult umbilical cord derived mesenchymal stem cell intravenous infusion for osteoporosis; URL: safety of cultured allogeneic adult umbilical cord derived mesenchymal stem cell intravenous infusion for osteoporosis - full text view - ClinicalTrials.gov Last accessed: July 28, 2022."},{"issue":"42","key":"10.1016\/j.berh.2022.101780_bib155","article-title":"The therapeutic potential of mesenchymal stem cells in treating osteoporosis","volume":"54","author":"Chen","year":"2021","journal-title":"Biol Res"},{"key":"10.1016\/j.berh.2022.101780_bib156","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"\u00c1lvaro-Gracia","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:23:26Z","timestamp":1761499406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694222000390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1521694222000390"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2022.101780","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoporosis and Fragility Fractures: currently available pharmacological options and future directions","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2022.101780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101780"}}